What is Cocrystal Pharma Intrinsic Value: Projected FCF?
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-29), Cocrystal Pharma's Intrinsic Value: Projected FCF is $-8.47. The stock price of Cocrystal Pharma is $1.5438. Therefore, Cocrystal Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Cocrystal Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Cocrystal Pharma was 11.28. The lowest was 6.28. And the median was 8.92.
COCP's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.32 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Cocrystal Pharma Intrinsic Value: Projected FCF Historical Data
The historical data trend for Cocrystal Pharma's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cocrystal Pharma's Intrinsic Value: Projected FCF
For the Biotechnology subindustry, Cocrystal Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma's Price-to-Projected-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Cocrystal Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
1.5438
/
-8.4664148851259
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cocrystal Pharma Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Cocrystal Pharma's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cocrystal Pharma (Cocrystal Pharma) Business Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COCP has been successfully added to your 